TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8680703

Group type: EXPERIMENTAL
Intervention: Initial bronchoalveolar lavage (BAL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Follow-up bronchoalveolar lavage (BAL) after 4 days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Initial IL-8 concentrations in BAL fluid
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Follow-up IL-8 concentrations in BAL fluid after 4 days
Number of subjects: 58
Study: 1404043

Group type: EXPERIMENTAL
Intervention: Calcium alginate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 34
Study: 3924425

Group type: EXPERIMENTAL
Intervention: 5 mile continuous exercise
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 4 minute interval (1:1, work:rest)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 minute interval (1:1-1/2, work:rest)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 31977602

Group type: EXPERIMENTAL
Intervention: synthDIR
Number of subjects: 100

Group type: COMPARATOR
Intervention: FLAIR
Number of subjects: 100

Group type: COMPARATOR
Intervention: trueDIR
Number of subjects: 100
Study: 29802293

Group type: EXPERIMENTAL
Intervention: eLearning
Number of subjects: 245

Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 245
Study: 27503640

Group type: COMPARATOR
Intervention: EDP-239 (100 mg single dose)
Number of subjects: 0
Study: 25436815

Group type: EXPERIMENTAL
Intervention: Daily multivitamin supplementation (B complex, C, and E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23108516

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 g orally
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg orally
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study: 19850639

Group type: EXPERIMENTAL
Intervention: CTC detection before chemotherapy
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: CTC detection after chemotherapy
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: CTC detection before neoadjuvant chemotherapy
Number of subjects: 115
Study: 18042474

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (BTDS)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 16136771

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12898832

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 471

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 471
Study: 10599797

Group type: EXPERIMENTAL
Intervention: 3,4-DL-threo-dihydroxyphenylserine (DL-DOPS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8557011

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.12, 0.17, 0.22 or 0.27 mg kg‐1, total dose of 0.5 mg kg‐1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Neostigmine administration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 56
Study: 1792341

Group type: EXPERIMENTAL
Intervention: Skin refrigerant/anesthetic
Number of subjects: 60

Group type: COMPARATOR
Intervention: Compressed air (Control)
Number of subjects: 60
Study: 7275464

Group type: EXPERIMENTAL
Intervention: 320 kcal diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 320 kcal diet with 75 micrograms of T3 daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-obese controls
Number of subjects: 0
Study: 30736834

Group type: EXPERIMENTAL
Intervention: VIA Family intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study: 30392276

Group type: EXPERIMENTAL
Intervention: TACE with bleomycin, pirarubicin, oxaliplatin, and fluorouracil
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group: TACE with pirarubicin, oxaliplatin, and fluorouracil
Number of subjects: 160
Study: 27059176

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (ICBT)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Number of subjects: 879

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 879
Study: 24165020

Group type: EXPERIMENTAL
Intervention: Testosterone 2% transdermal gel
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 22153256

Group type: EXPERIMENTAL
Intervention: Warfarin reinitiation in-hospital
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Warfarin reinitiation in selected patients
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Factors associated with restarting warfarin
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Initial international normalized ratio > 3.0
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Greater stroke severity
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Intraventricular hemorrhage
Number of subjects: 284
Study: 19948753

Group type: EXPERIMENTAL
Intervention: Targeted physiotherapy (T; n = 30)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Generalized physiotherapy (G; n = 27)
Number of subjects: 57
Study: 17714121

Group type: EXPERIMENTAL
Intervention: LC‐SSW‐UVB
Number of subjects: 143

Group type: COMPARATOR
Intervention: UVB
Number of subjects: 143
Study: 16315785

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 800 microg daily for 6 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12455155

Group type: EXPERIMENTAL
Intervention: D-003 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D-003 50 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D-003 5, 25 and 50 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10600434

Group type: EXPERIMENTAL
Intervention: Directly mailed smoking cessation intervention (personalized letter and self-help manual)
Number of subjects: 1858

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1858
Study: 8749687

Group type: EXPERIMENTAL
Intervention: Modeled bicarbonate dialysis (M; 28 mmol/L rising to 35 mmol/L at 3 h, 40 mmol/L at 4 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High bicarbonate dialysis (H; 40 mmol/L)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (S; dialysate HCO3- 30 to 34 mmol/L)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All treatments (S, H, M)
Number of subjects: 9
Study: 2344857

Group type: EXPERIMENTAL
Intervention: Infusion of 1.5 mg digoxin over 6 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bolus injections of 0.5 mg digoxin 8 hours apart (three injections)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11
Study: 7407759

Group type: EXPERIMENTAL
Intervention: IMPY administered via single iv bolus
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IMPY administered via intermittent 5-day bolus
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IMPY administered via 5-day continuous infusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IMPY
Number of subjects: 26
Study: 30177490

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesylate 2.5 mg orally twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dihydroergotoxine mesylate
Number of subjects: 30
Study: 27996280

Group type: EXPERIMENTAL
Intervention: Nebulized MgSO₄
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous MgSO₄
Number of subjects: 28
Study: 25838291

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) exposure in the first trimester
Number of subjects: 12888

Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine/ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 12888

Group type: COMPARATOR
Intervention: LPV/r
Number of subjects: 12888

Group type: EXPERIMENTAL
Intervention: ZDV exposure
Number of subjects: 12888
Study: 24219370

Group type: EXPERIMENTAL
Intervention: Carrageenan nasal spray, applied three times daily for seven days
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Carrageenan nasal spray
Number of subjects: 211

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 211
Study: 21425952

Group type: EXPERIMENTAL
Intervention: Sanitary pads with a nonwoven unique surface sheet
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sanitary pads with a perforated film
Number of subjects: 54
Study: 19729979

Group type: COMPARATOR
Intervention: Weekly docetaxel 40 mg/m² (group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel 35 mg/m² with gemcitabine 600 mg/m² (group B)
Number of subjects: 75
Study: 16424649

Group type: EXPERIMENTAL
Intervention: Intravenous anti-D (50 microg/kg i.v. initially, with repeated doses every 4 weeks for 12 patients)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-dose intravenous immunoglobulin (IVIG, 250 mg/kg for 2 consecutive days)
Number of subjects: 34
Study: 11006039

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m², Paclitaxel 200 mg/m², Cyclophosphamide 500 mg/m² with G-CSF 300 microg daily for 5 days, followed by Carboplatin AUC-5 and Paclitaxel 135 mg/m²
Number of subjects: 30
Study: 8699774

Group type: EXPERIMENTAL
Intervention: Indomethacin 1% eyedrops (Chibro‐Amuno ‐3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% eyedrops (Voltaren ophtha)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% eyedrops (Ocuflur)
Number of subjects: 90
Study: 1803242

Group type: EXPERIMENTAL
Intervention: 1% terbinafine cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% bifonazole cream
Number of subjects: 40
Study: 6337767

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of insulin [2.5 units h‐1 (m2 of body surface area)‐1]
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no insulin)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous angiotensin II (20 ng min‐1 kg‐1) with insulin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous angiotensin II (20 ng min‐1 kg‐1) without insulin
Number of subjects: 6
Study: 31554423

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clopidogrel (300 to 600 mg loading dose, 75 mg daily thereafter)
Number of subjects: 120
Study: 29477989

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (ARMA trial)
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Low positive end-expiratory pressure (ALVEOLI trial)
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Class 2 (from latent class analysis)
Number of subjects: 1022
Study: 26143741

Group type: EXPERIMENTAL
Intervention: 2.2 g marine n-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control oil (thistle oil)
Number of subjects: 92
Study: 25238769

Group type: EXPERIMENTAL
Intervention: Integrated Clinical Prediction Rule (iCPR)
Number of subjects: 0
Study: 22341868

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200mg daily for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19541675

Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Embol-X
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no additional device)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 143
Study: 17343662

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 44

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 44
Study: 15881488

Group type: EXPERIMENTAL
Intervention: Pioglitazone monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone monotherapy and pioglitazone plus sulfonylurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone plus metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfonylurea monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfonylurea plus metformin
Number of subjects: 0
Study: 12078335

Group type: EXPERIMENTAL
Intervention: Carbolithium Once‐A‐Day (600 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard Carbolithium (300 mg b.i.d.)
Number of subjects: 18
Study: 12038471

Group type: COMPARATOR
Intervention: Bread made with white flour
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Whole wheat bread
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fine ground whole wheat bread
Number of subjects: 26
Study: 7658536

Group type: EXPERIMENTAL
Intervention: RigiScan monitoring
Number of subjects: 521
Study: 31676301

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left VLPFC
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over right VLPFC
Number of subjects: 90
Study: 30887708

Group type: EXPERIMENTAL
Intervention: Heated and humidified low flow nasal cannula (HHLFNC), <4 liters per minute (LPM) oxygen
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard dry oxygen (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Heated and humidified low flow nasal cannula (HHLFNC)
Number of subjects: 32
Study: 28750133

Group type: COMPARATOR
Intervention: Lapatinib
Number of subjects: 652

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 652
Study: 26294281

Group type: EXPERIMENTAL
Intervention: Intra-operative hand reflexology
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 100
Study: 23456673

Group type: EXPERIMENTAL
Intervention: Tazarotene gel (3.7 g applied once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tazarotene foam (3.7 g applied once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tazarotene gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tazarotene foam and gel
Number of subjects: 0
Study: 21241910

Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol fixed combination, 1 drop immediately after surgery
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 58
Study: 19195263

Group type: EXPERIMENTAL
Intervention: Regular aerobic physical training during cardiovascular rehabilitation program for 6 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sedentary lifestyle group (control)
Number of subjects: 52
Study: 17825150

Group type: EXPERIMENTAL
Intervention: CTX + TBI
Number of subjects: 32

Group type: COMPARATOR
Intervention: CTX + ATG
Number of subjects: 32
Study: 15106795

Group type: EXPERIMENTAL
Intervention: Primary-care centers for diagnosis and follow-up
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Drug prescription patterns
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Consultations and medications
Number of subjects: 1000
Study: 11252223

Group type: EXPERIMENTAL
Intervention: Up-to-datedness score
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Inappropriateness score
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intraclass correlation for up-to-datedness
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intraclass correlation for inappropriateness
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intraclass correlation for preventive maneuvers
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sample size requirements
Number of subjects: 106
Study: 9850899

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (oxybuprocaine 0.4% drops)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Peribulbar anesthesia (lidocaine 2% and bupivacaine 0.5% with hyaluronidase)
Number of subjects: 100
Study: 7861719

Group type: EXPERIMENTAL
Intervention: Cyclosporin at an average dose of 3.9 mg/kg/day for up to three years
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment continued for an additional two years
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 19
Study: 2682864

Group type: EXPERIMENTAL
Intervention: Aerosol inhalation of salbutamol (SAL)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aerosol inhalation of N‐acetyl cysteine (AC)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CPT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined treatment with aerosol inhalation of SAL and AC followed by CPT (COMB)
Number of subjects: 19
Study: 412450

Group type: EXPERIMENTAL
Intervention: 5 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 10 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 20 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Second course of EHDP
Number of subjects: 109
Study: 31203381

Group type: EXPERIMENTAL
Intervention: Evaporative coolants
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ice packs
Number of subjects: 63
Study: 29070643

Group type: EXPERIMENTAL
Intervention: Functional bracing
Number of subjects: 330

Group type: COMPARATOR
Intervention: Plaster cast immobilisation
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Functional bracing and Plaster cast immobilisation
Number of subjects: 330
Study: 25777975

Group type: EXPERIMENTAL
Intervention: Social skill training and parent training (8-week sessions)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 23448807

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: gemcitabine plus AGS-1C4D4
Number of subjects: 196
Study: 21368751

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study: 18213728

Group type: EXPERIMENTAL
Intervention: Post-surgery tongue velocity during speech
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (6 normal adults)
Number of subjects: 10
Study: 17302257

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) 90 mg (1.0 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) 45 mg (2 x 0.5 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Injection vehicle (ENF buffer minus ENF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Cohort II - ENF-naive)
Number of subjects: 30
Study: 15017494

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10875491

Group type: EXPERIMENTAL
Intervention: Topical beclomethasone treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study: 9165598

Group type: EXPERIMENTAL
Intervention: Desmopressin treatment
Number of subjects: 3521
Study: 1589705

Group type: EXPERIMENTAL
Intervention: Doxycycline triple therapy (with bismuth subcitrate and metronidazole)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Tetracycline HCl triple therapy (with bismuth subcitrate and metronidazole)
Number of subjects: 73
Study: 3928490

Group type: EXPERIMENTAL
Intervention: LGX (laevulose 20%, glucose 10%, xylitol 10%)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glucose 50%
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LGX regime alone
Number of subjects: 6
Study: 31995720

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 29754384

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 80
Study: 27837181

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (USGFS) of the GSV
Number of subjects: 326
Study: 25135804

Group type: EXPERIMENTAL
Intervention: Font-enlarged labels
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pictogram-incorporated labels
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard labels
Number of subjects: 110
Study: 22527813

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (group 1)
Number of subjects: 99

Group type: COMPARATOR
Intervention: H. pylori eradication therapy (group 2)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 99
Study: 21302485

Group type: EXPERIMENTAL
Intervention: Paroxetine combined with Chaihu Xiaoyao Mixture (CXM)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 18006206

Group type: EXPERIMENTAL
Intervention: Tray based whitening system (Colgate Visible White PF Mint) using a 6% hydrogen peroxide gel applied in the tray twice daily for 30 min
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 49
Study: 14980755

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Other medical therapies (oral contraceptives and/or prostaglandin synthetase inhibitor)
Number of subjects: 63
Study: 11777881

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (2-4 g intravenously)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (intravenously)
Number of subjects: 105
Study: 9690948

Group type: COMPARATOR
Intervention: Nebuhaler (large volume spacer)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Volumatic (large volume spacer)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aerochamber (small volume spacer)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MDI alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebuhaler vs Volumatic
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebuhaler vs Aerochamber
Number of subjects: 10
Study: 8121740

Group type: EXPERIMENTAL
Intervention: Salted peas or green beans (10 occasions over 10 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unsalted peas or green beans (10 occasions over 10 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Breast milk feeding
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control food (not specified)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adult ratings of infants' responses
Number of subjects: 36